Monopar Therapeutics director exercises options, sells
The director’s option exercises and sales were effected under a Rule 10b5-1 plan executed on May 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Monopar Therapeutics (MNPR) director Kim R. Tsuchimoto reported option exercises and common-stock sales on November 2 and November 4, 2026. On November 2, she exercised options for 1,199 shares at $30 per share and sold 1,199 shares at a weighted-average price of $70.10 per share. On November 4, she exercised options for 856 shares at $30 and 2,035 shares at $14, and reported sales of 1,295 shares at a weighted-average $70.75, 996 shares at a weighted-average $71.35, and 600 shares at $72.21 per share.
All reported transactions were effected pursuant to a Rule 10b5-1 plan executed May 27, 2026. Separately, the filing lists 11,486 shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Insider Trade Summary 10b5-1
Exercise and Sale: 4,090 shares ($200K approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
Tsuchimoto Kim R
Role
Director
Sold
4,090 shs ($290K)
Approx. gross sale proceeds
$290K
Approx. exercise cost
$90K
Approx. pre-tax spread
$200K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F2 | 856 | $0.00 | $0.00 |
| Exercise | Stock Option F1, F3 | 2,035 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 856 | $30.00 | $26K |
| Exercise | Common Stock F1 | 2,035 | $14.00 | $28K |
| Sale | Common Stock F1, F5 | 1,295 | $70.75 | $92K |
| Sale | Common Stock F1, F6 | 996 | $71.35 | $71K |
| Sale | Common Stock F1 | 600 | $72.21 | $43K |
| Exercise | Stock Option F1, F2 | 1,199 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,199 | $30.00 | $36K |
| Sale | Common Stock F1, F4 | 1,199 | $70.10 | $84K |
| Holding | Common Stock F7 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 10,215 contracts (Direct);
Common Stock — 0 shares (Direct);
Common Stock — 11,486 shares (Indirect, See Footnote)
Footnotes (7)
- F1. This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05-27-2026.
- F2. On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.
- F3. On February 2, 2022, the reporting person was granted stock options to purchase up to 16,280 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. On July 1, 2024, 6,105 options were forfeited upon Ms. Tsuchimoto's retirement from the Company.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.13 to $71.098, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.14 to $71.58, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.
- F7. Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Key Figures
Options exercised and shares acquired: 1,199 shares at $30 per share
Shares sold: 1,199 shares at a weighted-average $70.10 per share
Options exercised and shares acquired: 856 shares at $30 per share
+5 more
8 metrics
Options exercised and shares acquired
1,199 shares at $30 per share
November 2, 2026
Shares sold
1,199 shares at a weighted-average $70.10 per share
November 2, 2026
Options exercised and shares acquired
856 shares at $30 per share
November 4, 2026
Options exercised and shares acquired
2,035 shares at $14 per share
November 4, 2026
Shares sold
1,295 shares at a weighted-average $70.75 per share
November 4, 2026
Shares sold
996 shares at a weighted-average $71.35 per share
November 4, 2026
Shares sold
600 shares at $72.21 per share
November 4, 2026
Trust-held common shares
11,486 shares
Held by the Kim R. Tsuchimoto Trust dated October 6, 2015; position listed November 2, 2026
Key Terms
Rule 10b5-1 Plan, weighted average price, vesting commencement date
3 terms
Rule 10b5-1 Plan regulatory
"effected pursuant to a Rule 10b5-1 Plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vesting commencement date financial
"vesting commencement date of October 1, 2018"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What options did MNPR director Kim R. Tsuchimoto exercise?
On November 2, 2026, she exercised options for 1,199 shares at $30 per share. On November 4, she exercised options for 856 shares at $30 per share and 2,035 shares at $14 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
